145 related articles for article (PubMed ID: 35644725)
21. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C; Hennemann A; Diallo K; Funck-Brentano E; Puzenat E; Heidelberger V; Jeudy G; Samimi M; Lesage C; Boussemart L; Peuvrel L; Rouanet J; Brunet-Possenti F; Gerard E; Seris A; Jouary T; Saint-Jean M; Puyraveau M; Saiag P; Aubin F
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509227
[TBL] [Abstract][Full Text] [Related]
24. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
25. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
27. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
[TBL] [Abstract][Full Text] [Related]
28. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
29. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Eijs MJM; de Groot JB; Hospers GAP; Kapiteijn E; de Meza M; Piersma D; Stevense-den Boer M; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Suijkerbuijk KPM; Blokx WAM
Eur J Cancer; 2023 Jun; 186():27-37. PubMed ID: 37023588
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P; Ahmed T; Lo SN; Shoushtari A; Zaremba A; Versluis JM; Mangana J; Weichenthal M; Si L; Lesimple T; Robert C; Trojanello C; Wicky A; Heywood R; Tran L; Batty K; Dimitriou F; Stansfeld A; Allayous C; Schwarze JK; Mooradian MJ; Klein O; Mehmi I; Roberts-Thomson R; Maurichi A; Yeoh HL; Khattak A; Zimmer L; Blank CU; Ramelyte E; Kähler KC; Roy S; Ascierto PA; Michielin O; Lorigan PC; Johnson DB; Plummer R; Lebbe C; Neyns B; Sullivan R; Hamid O; Santinami M; McArthur GA; Haydon AM; Long GV; Menzies AM; Carlino MS
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793872
[TBL] [Abstract][Full Text] [Related]
33. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
35. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV
Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
Saijo K; Imai H; Ouchi K; Okada Y; Sato Y; Komine K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
Tohoku J Exp Med; 2019 May; 248(1):37-43. PubMed ID: 31105123
[TBL] [Abstract][Full Text] [Related]
37. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
38. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
39.
van Not OJ; Blokx WAM; van den Eertwegh AJM; de Meza MM; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer M; van der Veldt AAM; Boers-Sonderen MJ; Jansen AML; Wouters MWJM; Suijkerbuijk KPM
JCO Precis Oncol; 2022 Sep; 6():e2200018. PubMed ID: 36130145
[TBL] [Abstract][Full Text] [Related]
40. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
